Elucidating the role of androgen receptor in breast cancer
Although Breast carcinoma had many targeted biomarkers for its treatment, however, it is a heterogeneous disease with different outcomes and need new markers especially for the triple negative group when estrogen receptor, progesterone receptors and Her2/neu are negative.
AR: ER ratio is also an independent predictor of disease-free survival (HR = 4.04, 95% CI: 1.68, 9.69; p = 0.002) and disease specific survival (HR = 2.75, 95% CI: 1.11, 6.86; p = 0.03).
Its expression is associated significantly with both the stage and the grade.
Also it was significantly associated with estrogen receptor and Her2/neu expression.
In the present review we first discuss the epidemiological data linking a hyperandrogen state to a higher risk for ovarian cancer, second describe in vitro studies of the role of androgens in influencing the growth of EOC, and finally review the completed clinical trials with compounds that exploit the androgen axis in patients with ovarian cancer.
The therapeutic approaches that inhibit androgen signaling have so far produced only modest response rates.In its basal state, AR is inactive and is bound to heatshock proteins and other cellular chaperones.